Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration

Journal of Neuroscience Research

Volumn 78, Issue 1, 2004, Pages 87-91

  Stefanova, Nadia ^a   Mitschnigg, Monika ^a   Ghorayeb, Imad ^b   Diguet, Elsa ^b   Geser, Felix ^a   Tison, Francois ^b   Poewe, Werner ^a   Wenning, Gregor K ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b CNRS   (France)

Author keywords

Astrogliosis; Microglial activation; Minocycline; Multiple system atrophy; Neuroprotection

Indexed keywords

LEVODOPA; MINOCYCLINE; PHOSPHOPROTEIN DARPP 32;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BLOOD BRAIN BARRIER; BRAIN SIZE; CELL ACTIVATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GLIA CELL; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MACROGLIA; MALE; MICROGLIA; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SHY DRAGER SYNDROME; STRIATONIGRAL DEGENERATION; TREATMENT FAILURE;

ANIMALS; DISEASE MODELS, ANIMAL; MALE; MINOCYCLINE; NEUROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; STRIATONIGRAL DEGENERATION;

EID: 4644258413     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20233     Document Type: Article

References (31)

1. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. 1997. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49:1284-1288.
2. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM. 2000. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801.
3. Diguet E, Rouland R, Tison F. 2003. Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease. Ann Neurol 54:841-842.
4. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM. 2001. Minocyeline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98:14669-14674.
5. Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN, Turkheimer F, Good CD, Mathias CJ, Quinn N, Schwarz J, Brooks DJ. 2003. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 61:686-689.
6. Ghorayeb I, Puschban Z, Fernagut PO, Scherfler C, Rouland R, Wenning GK, Tison F. 2001. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. Exp Neurol 167:133-147.
7. He Y, Appel S, Le W. 2001. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909:187-193.
8. Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T, Hirose T. 2004. Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 63:43-52.
9. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Wakabayashi K, Bogdanovic N, Riederer P, Kretzschmar HA, Haass C. 2002. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 3:583-588.
10. Lin S, Wei K, Ku Y, Van C, Dodel R, Zhang Y, Liu J, Klaunig JE, Farlow M, Du Y. 2003. Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sci 72:1635-1641.
11. Oo TF, Siman R, Burke RE. 2002. Distinct nuclear and cytoplasmic localization of caspase cleavage products in two models of induced apoptotic death in dopamine neurons of the substantia nigra. Exp Neurol 175:1-9.
12. Puschban Z, Scherfler C, Granata R, Laboyrie P, Quinn NP, Jenner P, Poewe W, Wenning GK. 2000a. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts. Neuroscience 95:377-388.
13. Puschban Z, Waldner R, Seppi K, Stefanova N, Humpel C, Scherfler C, Levivier M, Poewe W, Wenning GK. 2000b. Failure of neuroprotection by embryonic striatal grafts in a double lesion nit model of striatonigral degeneration (multiple system atrophy). Exp Neurol 164:166-175.
14. Ryan ME, Ashley RA. 1998. How do tetracyclines work? Adv Dent Res 12:149-151.
15. Scherfler C, Puschban Z, Ghorayeb I, Goebel GP, Tison F, Jellinger K, Poewe W, Wenning GK. 2000. Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). Neuroscience 99:43-54.
16. Schrag A, Ben-Shlomo Y, Quinn NP. 1999. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354:1771-1775.
17. Schwarz SC, Seufferlein T, Liptay S, Schmid RM, Kasischke K, Foster OJ, Daniel S, Schwarz J. 1998. Microglial activation in multiple system atrophy: a potential role for NF-kappaB/rel proteins. Neuroreport 9:3029-3032.
18. Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PA, Bates GP, Hoekly E. 2003. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 54:186-196.
19. Stefanova N, Lundblad M, Tison F, Poewe W, Cenci MA, Wenning GK. 2004. Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). Neurobiol Dis 15:630-639.
20. Stefanova N, Puschban Z, Fernagut PO, Brouillet E, Tison F, Reindl M, Jellinger KA, Poewe W, Wennnig GK. 2003. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). Acta Neuropathol (Berl) 106: 157-166.
21. Stefanova N, Sather T, Poewe W, Wenning GK. 2002. Protective effect of riluzole in a double lesion rat model of striatonigral degeneration (multiple system atrophy). Mov Disord 17(Suppl):259.
22. von Cramon D, Kelemen J. 1973. Glial change's in olivo-pouto-cerebellar atrophies and their significance for formal pathogenesis. Acta Neuropathol (Berl) 25:14-26.
23. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM. 2003. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 100:10483-10487.
24. Wenning CK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. 1994. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 117:835-845.
25. Wenning CK, Colosimo C, Geser F, Poewe W. 2004. Multiple system atrophy. Lancet Neurol 3:93-103.
26. Wenning GK, Granata R, Laboyrie PM, Quinn NP, Jenner P, Marsden CD. 1996. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Mov Disord 11:522-532.
27. Wenning GK, Granata R, Puschban Z, Scherfler C, Poewe W. 1999. Neural transplantation in animal models of multiple system atrophy: a review. J Neural Transm Suppl 55:103-113.
28. Wenning CK, Seppi K, Tison F, Jellinger K. 2002. A novel grading scale for striatonigral degeneration (multiple system atrophy). J Neural Transm 109:307-320.
29. Wenning GK, Tison F, Scherfler C, Puschban Z, Waldner R, Granata R, Ghorayeb I, Poewe W. 2000. Towards neurotransplantation in multiple system atrophy: clinical rationale, pathophysiological basis, and preliminary experimental evidence. Cell Transplant 9:279-288.
30. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiroponlos H, Przedborski S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tctrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763-1771.
31. Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, Albers DS. 2003. Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci ResEuropeans 74: 278-285.